SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT<sub>7</sub> receptor partial inverse agonist, and was the first such ligand identified for 5-HT<sub>7</sub>. Its use in research has mainly been in demonstrating the potential use for 5-HT<sub>7</sub> agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT<sub>7</sub> agonists across several different testing models.